newsfilter
← Latest News
GlobeNewswire·

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

ZUG, Switzerland, November 5, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on advancing therapies to address significant unmet needs in inflammatory skin